Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

07/01/2016 - 2 minutes

Complix is a Belgian Immuno-Oncology Biotech with a proprietary Alphabody platform, which has now attracted a €260M strategic drug discovery collaboration with Merck Sharp & Dohme (MSD).

complix_msd_merck_co_alphabody_cancerUnder the terms of the agreement, Complix will use its proprietary Alphabody platform to tackle two intra-cellular cancer targets. One example is the myeloid leukemia cell-1 protein (MCL-1), which regulates cell-death.

Initial in vivo data generated with their anti-MCL-1 alphabodies suggest they should have a good safety profile for a range of cancers, particularly hematological types (e.g. leukemia).

MSD will now provide an upfront payment (and potential development milestones) of up to €260M ($280M), as well as tiered royalties. In exchange, MSD will have an option to file exclusive worldwide rights to any successful Cell Penetrating Alphabodies (CPABs) which rise out of the research partnership.

CPABs enter tumor cells and tissues to selectively modulate intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of cancer.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member